Zhang A, Nanni R G, Li T, Arnold G F, Oren D A, Jacobo-Molina A, Williams R L, Kamer G, Rubenstein D A, Li Y
Center for Advanced Biotechnology and Medicine (CABM), Piscataway, NJ 08854-5638.
J Mol Biol. 1993 Apr 5;230(3):857-67. doi: 10.1006/jmbi.1993.1206.
SCH 38057 (1-[6-(2-chloro-4-methoxyphenoxy)-hexyl]imidazole hydrochloride) is a new, water-soluble antiviral compound that has inhibitory activities against a number of picornavirus infections. The structure of the human rhinovirus 14 (HRV14) complex with SCH 38057 was determined at 3.0 A resolution by single-crystal diffraction techniques using synchrotron X-radiation. SCH 38057 was found to bind at the innermost end of the hydrophobic pocket within the capsid protein VP1, a locus of binding of other antipicornaviral agents; however, the complex differs from previously reported complexes in two important aspects. It leaves a considerable volume near the entrance to the binding pocket unoccupied. In addition, the alterations in the conformation of the VP1 polypeptide are similar to, but more extensive than those observed in HRV14 complexes with other antiviral agents. Although only 9 amino acids of VP1 have close contacts with the SCH 38057 molecule (within 3.6 A), at least 36 amino acids from both VP1 and VP3 have significantly altered conformations (C alpha movement > 0.5 A versus native). The structures of complexes of HRV14 with SCH 38057 and WIN 51711 are compared. Aromatic ring interactions between picornavirus capsid residues and antiviral inhibitors are proposed to be among the major determinants for positioning of these compounds.
SCH 38057(1-[6-(2-氯-4-甲氧基苯氧基)-己基]咪唑盐酸盐)是一种新型的水溶性抗病毒化合物,对多种小核糖核酸病毒感染具有抑制活性。利用同步加速器X射线,通过单晶衍射技术,以3.0埃的分辨率测定了人鼻病毒14(HRV14)与SCH 38057的复合物结构。研究发现,SCH 38057结合在衣壳蛋白VP1内疏水口袋的最内侧,这也是其他抗小核糖核酸病毒药物的结合位点;然而,该复合物在两个重要方面与先前报道的复合物不同。它在结合口袋入口附近留下了相当大的未占据空间。此外,VP1多肽构象的改变与在HRV14与其他抗病毒药物形成的复合物中观察到的相似,但更为广泛。虽然VP1中只有9个氨基酸与SCH 38057分子有紧密接触(距离在3.6埃以内),但VP1和VP3中至少有36个氨基酸的构象发生了显著变化(相对于天然状态,Cα移动>0.5埃)。比较了HRV14与SCH 38057和WIN 51711形成的复合物的结构。小核糖核酸病毒衣壳残基与抗病毒抑制剂之间的芳香环相互作用被认为是这些化合物定位的主要决定因素之一。